Incyte Corporation (INCY)
Incyte is a US-based biopharmaceutical company that discovers and develops medicines to treat cancer and serious inflammatory conditions.
Is Incyte Corporation a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong profit margins indicate an efficient business model. Worth weighing: Does not pay a dividend, so no regular income for shareholders.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Incyte Corporation do?
Incyte focuses on finding new ways to treat complex diseases, primarily through its expertise in immunology and oncology. Sales of these specialised medicines to hospitals and pharmacies around the world bring in the revenue. Its fortunes hinge on how well their current drugs perform in the market and whether their pipeline of new treatments can successfully pass clinical trials.
On our factor screen it looks strongest on quality and growth, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 38% over the year
- ✓Very profitable - turns about 28% of sales into profit
- ✓Low debt - a sturdier balance sheet
- ✓Strong return on shareholder money (ROE 31%)
- Quality screens high
- Growth screens high
- Momentum screens high
- Income screens low
Does Incyte Corporation pay a dividend?
No - Incyte Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Incyte Corporation have more cash or more debt?
It holds about $4.54B in cash against about $38.27M of debt - so it has net cash of about $4.50B. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Incyte Corporation's numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Incyte Corporation actually fallen?
Over the last 2 years of daily prices, Incyte Corporation fell as much as −34% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Incyte Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of Incyte Corporation's sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £44 covers making the product or service, £28 goes on running costs, tax and interest, and about £28 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does Incyte Corporation report earnings, and how did recent quarters go?
Incyte Corporation is next scheduled to report on about 2026-10-27 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-28 | $2.15 | $3.09 | Beat +44% |
| 2026-04-28 | $1.34 | $1.81 | Beat +35% |
| 2026-02-10 | $1.92 | $1.80 | Missed -6% |
| 2025-10-28 | $1.64 | $2.26 | Beat +38% |
| 2025-07-29 | $1.47 | $1.57 | Beat +7% |
| 2025-04-29 | $1.03 | $1.16 | Beat +12% |
Across the last 6 quarters here, Incyte Corporation came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Incyte Corporation?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Breakthrough success of a new drug in the pipeline
Failure of key research projects to reach the market
What are the pros and cons of Incyte Corporation?
A balance check, not a score or verdict.
- Strong profit margins indicate an efficient business model
- Impressive recent growth in both revenue and earnings
- Lower volatility compared to the broader market
- Does not pay a dividend, so no regular income for shareholders
- High reliance on the success of a limited number of drugs
- The pharmaceutical industry is notoriously expensive and slow to innovate
- Clinical trials may fail, leading to wasted research spending
- Government changes to drug pricing could hit future profits
- Competitors may launch more effective or cheaper treatments
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial
- A significant change in government healthcare policy affecting drug reimbursement
Common questions about Incyte Corporation
Does Incyte Corporation pay a dividend?
No - Incyte Corporation does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Incyte Corporation report earnings next?
Incyte Corporation is next scheduled to report results on about 2026-10-27. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Agilent Technologies, Inc.
Viatris Inc.
CVS Health CorporationBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.